Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA
jarmoluk / Pixabay

Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA

According to a story from Globe Newswire, the biotechnology company Wave Life Sciences recently announced that its investigational product WVE-210201 has received both Rare Pediatric disease designation and Orphan Drug…

Continue Reading Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA
Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa
LaCasadeGoethe / Pixabay

Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa

Two companies, GtreeBNT and YuYang DNU, will collaborate in a joint venture to develop the investigational drug RGN-137 for the treatment of epidermolysis bullosa. For more details, you can read…

Continue Reading Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa
Study Finds That BRAF Inhibitors Could be an Effective Treatment for Some Ovarian Cancer Patients
felixioncool / Pixabay

Study Finds That BRAF Inhibitors Could be an Effective Treatment for Some Ovarian Cancer Patients

According to a story from news-medical.net, a recent study suggests that a class of drugs called BRAF inhibitors could be an effective treatment option for ovarian cancer patients who carry…

Continue Reading Study Finds That BRAF Inhibitors Could be an Effective Treatment for Some Ovarian Cancer Patients
So Why DOES Canada have Scarcer Access to Rare Disease Therapies?
FrankWinkler / Pixabay

So Why DOES Canada have Scarcer Access to Rare Disease Therapies?

According to a story from CheckOrphan, Durhane Wong-Rieger, the CEO of the Canadian Organization for Rare Disorders, says that the Canadian health system has been letting down the roughly three…

Continue Reading So Why DOES Canada have Scarcer Access to Rare Disease Therapies?
An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation
stevepb / Pixabay

An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation

The US FDA has awarded Breakthrough Therapy Designation to encorafenib (braftoviTM) combined with binimetinib (mektovi®) and cetuximab for use as an investigational (not FDA-approved) treatment of BRAFV600E–mutant metastatic colorectal cancer.…

Continue Reading An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation

The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  A Biologics License Application for ElzonrisTM (also known as tagraxofusp and SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm has been accepted for filing by the United States FDA.…

Continue Reading The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Possible Breakthrough Therapy for Premature Babies with Bronchopulmonary Dysplasia
https://pixabay.com/en/baby-care-child-cute-hand-face-20339/

Possible Breakthrough Therapy for Premature Babies with Bronchopulmonary Dysplasia

According to 9News, Harry Campbell was born very premature at 27 weeks. Not only this, but his dimensions were almost unfathomable. Harry was able to fit into the palm of…

Continue Reading Possible Breakthrough Therapy for Premature Babies with Bronchopulmonary Dysplasia
Orphan Drug Status Has Been Awarded to an Investigational Drug For the Treatment of Stomach Cancer
Free-Photos / Pixabay

Orphan Drug Status Has Been Awarded to an Investigational Drug For the Treatment of Stomach Cancer

An investigational drug called ALT-P7 is being developed as a potential medicine for certain forms of cancer. The drug has received Orphan Drug Designation for the treatment of gastric cancer…

Continue Reading Orphan Drug Status Has Been Awarded to an Investigational Drug For the Treatment of Stomach Cancer
Guidelines for Rare Pregnancy-Related Cancers Released for the First Time
Source: Pixabay

Guidelines for Rare Pregnancy-Related Cancers Released for the First Time

According to a story from Newswise, an organization called the National Comprehensive Cancer Network (NCCN) has recently released treatment guidelines for a rare type of cancer that can affect women…

Continue Reading Guidelines for Rare Pregnancy-Related Cancers Released for the First Time

The FDA Has Granted Orphan Drug Status to an Experimental Drug to Treat Amyloidosis

The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation to the experimental drug ALN-TTRsc02. Alnylam Pharmaceuticals Inc. is developing ALN-TTRsc02 as a possible treatment for transthyretin-mediated amyloidosis.…

Continue Reading The FDA Has Granted Orphan Drug Status to an Experimental Drug to Treat Amyloidosis
First Major Treatment Advance for PV Has Been Approved by the FDA
Source: pixabay.com

First Major Treatment Advance for PV Has Been Approved by the FDA

  According to BioSpace, a new treatment for pemphigus vulgaris (PV) has been recently approved by the U.S. Food and Drug Administration. The treatment, Rituxan (rituximab), is geared towards adults who have…

Continue Reading First Major Treatment Advance for PV Has Been Approved by the FDA
Orphan Drug Designation Has Been Awarded to Selumetinib for the Treatment of Neurofibromatosis Type 1
Source: Pixabay.com

Orphan Drug Designation Has Been Awarded to Selumetinib for the Treatment of Neurofibromatosis Type 1

The European Medicines Agency has awarded Orphan Drug designation to selumetinib for the treatment of neurofibromatosis type 1. You can read the source press release here, on Merck’s website. About…

Continue Reading Orphan Drug Designation Has Been Awarded to Selumetinib for the Treatment of Neurofibromatosis Type 1